Obatoclax

Obatoclax
Names
	IUPAC name 2-(2-((3,5-Dimethyl-1H-pyrrol-2-yl)methylene)-3-methoxy-2H-pyrrol-5-yl)-1H-indole
	Other names GX15-070
Identifiers
CAS Number	803712-67-6 ; 803712-79-0 (mesylate) ;
3D model (JSmol)	Interactive image;
ChemSpider	24539359;
PubChem CID	11404337; 16681698 (mesylate);
UNII	QN4128B52A ;
	InChI InChI=1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21-22H,1-3H3/b19-10+;
	SMILES Cc1cc([nH]c1/C=C/2\C(=CC(=N2)c3cc4ccccc4[nH]3)OC)C;
Properties
Chemical formula	C20H19N3O
Molar mass	317.392 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Obatoclax is an experimental drug candidate for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon.^[1] It is in Phase II clinical trials for the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.^[2]^[3]^[4]

Mechanism of action

Obatoclax is an inhibitor of the Bcl-2 family of proteins.^[5] This inhibition induces apoptosis in cancer cells, preventing tumor growth.

^ Cephalon Announces Definitive Agreement to Acquire Gemin X, March 21, 2011
^ Parikh, Sameer A.; Kantarjian, Hagop; Schimmer, Aaron; Walsh, William; Asatiani, Ekatherine; El-Shami, Khaled; Winton, Elliott; Verstovsek, Srdan (2010). "Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis". Clinical Lymphoma, Myeloma & Leukemia. 10 (4): 285–289. doi:10.3816/CLML.2010.n.059.
^ Gemin X Presents New Data on Obatoclax at the American Society of Hematology Meeting, Dec 9, 2008
^ Obatoclax at ClinicalTrials.gov
^ Konopleva, Marina; Watt, Julie; Contractor, Rooha; Tsao, Twee; Harris, David; Estrov, Zeev; Bornmann, William; Kantarjian, Hagop; Viallet, Jean; Samudio, Ismael; Andreeff, Michael (2008). "Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)". Cancer Research. 68 (9): 3413–3420. doi:10.1158/0008-5472.CAN-07-1919. PMID 18451169.